According to the latest quarterly results, RPG Life Sciences reported net profit of ₹22.13 crores in Q3 FY26, representing a steep 39.95% quarter-on-quarter contraction from ₹36.85 crores in Q2 FY26. While revenue remained largely stable at ₹180.03 crores with only a marginal 0.91% sequential decline, the company faced unprecedented margin compression that severely impacted bottom-line performance. The net profit margin compressed dramatically from 20.28% in Q2 FY26 to 12.29% in Q3 FY26, marking the lowest quarterly profit in recent periods and raising concerns about operational efficiency and competitive positioning.
The most alarming aspect of Q3 FY26 results was the gross profit margin collapse from 30.09% in Q2 FY26 to 19.16% in Q3 FY26, a concerning 1,093 basis point deterioration. This unprecedented margin compression suggests significant pressure on product pricing power, adverse product mix shifts, or substantial raw material cost inflation that the company has been unable to pass through to customers. While operating profit (PBDIT excluding other income) improved marginally to ₹39.76 crores from ₹39.03 crores, the profit before tax plummeted 41.12% to ₹29.12 crores from ₹49.45 crores, highlighting the severity of margin pressures across the business.
The shareholding pattern for Q3 FY26 reveals a dramatic shift in institutional investor sentiment, with mutual funds slashing their stake from 3.20% in Q2 FY26 to just 0.04% in Q3 FY26—a massive 3.16 percentage point reduction. This exodus of mutual fund investors represents a significant vote of no confidence in the company's near-term prospects. Foreign Institutional Investors (FII) also continued their gradual exit, reducing stakes from 1.11% to 1.00%, while overall institutional holding remains modest at 8.04%. The promoter holding remained stable at 72.95% with zero pledging, providing some stability amid the institutional investor concerns.
Despite the profitability headwinds, the Active Pharmaceutical Ingredients (API) segment continues to show strong performance, contributing significantly to revenue stability. As previously reported by CNBC-TV18, the API segment momentum that was evident from January has sustained through Q3, helping maintain top-line growth despite margin pressures. The domestic portfolio continues to demonstrate robust characteristics, supporting the company's ability to achieve revenue stability even as operational challenges impacted overall profitability across key business segments.
The stock declined 2.16% to ₹2,089.30 following the results announcement, reflecting investor concerns over deteriorating margins and sequential profit compression. RPG Life Sciences has significantly underperformed the broader market, declining 6.11% over the past week and 11.42% over the past month against the Sensex's more modest declines. The stock is trading below all key moving averages and has shifted to a bearish trend since January 16, 2026. At current levels, the company trades at a P/E ratio of 31 times trailing twelve-month earnings, which appears reasonable given the superior return on equity of 21.68%, though recent operational trends raise questions about sustainability.
